Portman Square Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-120,500
Closed -$25.2M 181
2025
Q1
$25.2M Buy
120,500
+110,500
+1,105% +$21.5M 0.67% 47
2024
Q4
$1.78M Sell
10,000
-1,100
-10% -$202K 0.06% 183
2024
Q3
$2.19M Hold
11,100
0.08% 214
2024
Q2
$1.9M Sell
11,100
-24,000
-68% -$3.98M 0.07% 229
2024
Q1
$6.39M Sell
35,100
-8,900
-20% -$1.53M 0.18% 136
2023
Q4
$6.82M Buy
44,000
+15,100
+52% +$2.2M 0.16% 158
2023
Q3
$4.31M Hold
28,900
0.11% 201
2023
Q2
$3.89M Buy
28,900
+16,300
+129% +$2.39M 0.11% 174
2023
Q1
$2.01M Buy
12,600
+4,400
+54% +$673K 0.09% 162
2022
Q4
$1.33M Buy
+8,200
New +$1.26M 0.1% 174

Other funds holding ABBV

Portman Square Capital's ABBV Position: Q3 2024 in Review

Portman Square Capital sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 1,828 shares — an estimated $341K sold.

Portman Square Capital first reported a position in ABBV in Q1 2023 and held it in 6 quarters. The position peaked at $2.25M in Q2 2023. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Portman Square Capital reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Portman Square Capital sold 1,828 AbbVie shares in Q3 2024, an estimated $341K.
  • Portman Square Capital first reported a position in AbbVie in Q1 2023 and held it in 6 quarters.
  • Portman Square Capital's AbbVie position peaked at $2.25M in Q2 2023.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Portman Square Capital's 13F filing for Q3 2024, filed 16 Oct 2024.